Liquid Biopsy in Squamous Cell Carcinoma of the Esophagus and of the Head and Neck

Razvan Iacob 1,2,3†, Matei Mandea 1†, Speranta Iacob 1,2,3, Catalina Pietrosanu 1,4, Doru Paul 5, Razvan Hainarosie 1,4* and Cristian Gheorghe 1,2,3

1 University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 2 Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Romania, 3 Center of Excellence in Translational Medicine, Fundeni Clinical Institute, Bucharest, Romania, 4 Professor Doctor Dorin Hociota Institute of Phonoaudiology and Functional ENT Surgery, Bucharest, Romania, 5 Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, United States

Squamous cell carcinomas of the esophagus (ESCC) and of the head and neck (HNSCC) are two neoplasms that share common risk factors and have the same embryological origin, but a very different prognosis, the 5-year survival of HNSCC being almost double (40–50%) compared to the 5-year survival of ESCC (20%). Current guidelines emphasize the importance of screening for ESCC in patients diagnosed with head and neck cancers. A liquid biopsy is a novel tool for diagnosis, prognostic stratification, and personalized therapy. Liquid biopsy biomarkers for these two malignancies could help both their early detection, facilitate residual disease identification, and provide prognosis information. The present systematic review of the literature was aimed at describing the liquid biopsy biomarkers present in these two malignancies, with an emphasis on potential clinical applications.

Keywords: liquid biopsy, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, cell free DNA, circulating tumor cells, exosomes

INTRODUCTION

Squamous cell carcinoma of the esophagus (ESCC) and of the head and neck are common neoplastic pathologies being responsible of over 500,000 deaths per year, with an increased incidence in the past few years. The head and neck squamous cell carcinoma (HNSCC) can arise from tissues of the oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx. According to the GLOBOCAN 2020, the incidence of HNSCC has increased worldwide in the last decade, with more than 800,000 new cases every year, with cancer of the oral cavity and lips being the most frequent (1). The most important risk factors are smoking, human papillomavirus (HPV) infection, and alcohol abuse, with an increased number of cases in males (2–4). The diagnosis is often made in a late stage due to suboptimal conventional biomarkers for early-stage disease. 40% of patients are diagnosed when lymph nodes metastasis is present and the outcome is poor (2, 3). Currently, the diagnosis consists of imaging methods associated with tissue biopsy (3). Despite recent advances in locoregional therapies, up to 60% of HNSCC tumors will have a locoregional recurrence and additional 20% will develop distant metastasis, leading to treatment failure (5). The tumor HPV assessed by p16 expression is currently the most widely used biomarker in HNSCC (6). Overall, HNSCC has a 40–50% 5-year survival.
The ESCC is often diagnosed in a late stage, with a <20% survival at 5 years from diagnosis. The incidence has decreased in the past decade due to smoking cessation, but there are still over 600,000 new cases diagnosed every year (1). ESCC ranks as the sixth cause of cancer-related mortality worldwide, with an age-standardized rate/100,000 (ASR) of 5.6. Currently, screening for ESCC is recommended also for patients with a personal or familial history of head and neck cancers and is based on upper gastrointestinal endoscopy. The use of carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) do not have good sensitivity in detecting early cases of ESCC and are not recommended as routine screening tests in clinical practice (7–9).

Although HNSCC and ESCC share common risk factors, such as tobacco usage, alcohol abuse, male sex, and other risk factors are specific for each type, such as HPV infection and poor oral hygiene for HNSCC and hot food and beverages and changes in diet (9–11). Several studies have documented that the presence of HNSCC and ESCC in the same patient leads to decreased longevity and increased morbidity, especially when surgical resection is conducted for both the malignancies (11, 12). Currently, high-resolution chromoendoscopy or virtual chromoendoscopy using NBI or I-SCAN techniques is the gold standard for early diagnosis of ESCC and endoscopic resection of early ESCC is the best therapeutic option (13). As radiation therapy conducted in HNSCC might induce radiation esophagitis with or without strictures, alternative methods of molecular diagnosis that could indicate the potential coexistence of ESCC are clearly useful. Therefore, the identification of markers for early diagnosis and posttreatment disease monitoring are of paramount importance for both the malignancies, as early diagnosis is the cornerstone of curative therapies. Considering that the two anatomical sites share a common embryological origin and common risk factors, one could expect to find common molecular markers that could be used for the early detection and prognosis of both the malignancies. At the same time, tumor-specific molecular markers would further refine our ability to stratify patients both for the diagnostic and prognostic purposes and for treatment that is different in these two conditions.

LIQUID BIOPSY AS A NOVEL TOOL FOR DIAGNOSIS AND PROGNOSIS

Liquid biopsy has recently emerged as a new non-invasive technique of detecting blood circulating biomarkers. There are multiple applications of liquid biopsy currently investigated both for ESCC and HNSCC (3, 14, 15), for example, detection of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and exosomes-based biomarkers (16, 17).

Circulating Tumor Cells

Circulating tumor cells represent cancer cells derived from the primary site of neoplasia that are shed in the bloodstream or in the lymphatics and are responsible for metastatic progression of the disease (16, 17). They can be used as diagnostic or prognosis markers, being useful for estimating the tumor dynamics. The detection of CTCs is based on markers expression on the surface and in the cytoplasm of the CTCs (17).

Cell-Free DNA (CdNA)

Cell-free DNA is released in the bloodstream during necrosis and apoptosis of cells. The tumoral source of cdDNA is represented by ctDNA and it is present along cdDNA originating from normal cells, as a fraction of the total circulating free DNA. Valuable tumor information like somatic mutations or methylation profiles could be detected through specific methods such as next-generation sequencing (NGS) and are important for early disease detection, detection of residual disease following therapy, personalized therapeutic tailoring, and prognostic estimation (15, 16, 18).

Exosomes

Exosomes are stable extracellular vesicles of small size (40–150 nm), released by cells in various body fluids, containing proteins, microRNAs (miRNA), messenger RNA (mRNA), DNA, and long noncoding RNA (lncRNA) (16). miRNAs and lncRNAs are included in the category of regulatory noncoding RNAs. miRNA consists of 20–24 nucleotides, with important roles in cell differentiation, proliferation, apoptosis as well as in tumor suppression or promotion, by regulating the expression of multiple target genes (16, 19, 20). LncRNAs are RNAs consisting of over 200 nucleotides that do not code proteins and are released by tumoral cells also via exosomes (20).

SYSTEMATIC LITERATURE REVIEW

The scope of the present review was to systematically perform a literature search to identify biomarkers of liquid biopsy significant for diagnosis and prognosis of ESCC and HNSCC, respectively, with a special focus on biomarkers shared by the two cancers. Pubmed and CrossRef were used to search for original articles that were published between 2001 and 2021 using HNSCC and ESCC medical subject heading (MeSH) terms combined with terms liquid biopsy, CTCs, cdDNA, circulating-tumoral DNA, exosomes, and miRNA. The systematic literature search was conducted in March to August 2021. The literature was initially screened for types of liquid biopsy used in both the HNSCC and ESCC, further investigating whether markers are common or different depending on the type of cancer investigated.

CIRCULATING TUMOR CELLS IN HNSCC

Two excellent recent publications, a systematic review and a meta-analysis have addressed the utility of CTCs in diagnostic and prognosis of HNSCC (17, 21). Most representative papers on this subject consist of nine prospective cohort studies and one retrospective cohort study (5, 22–30). The studies are heterogeneous in terms of disease staging, including either patients diagnosed in stages I–IV or only advanced disease cases (stages III–IV). Similarly, significant heterogeneity was noted about the timing of the study, before, during, or after
treatment, or about the types of treatment (surgery, radiotherapy, or chemotherapy).

Several techniques were used for CTC isolation, such as negative enrichment immunofluorescence in situ hybridization (Ne imFISH), the use of CellSearch or Clearcell FX platforms, by staining with immunofluorescent antibodies to specific cytokeratins, or by detection of Epidermal Growth Factor Receptor (EGFR) transcripts (23, 25, 26, 29, 31). The most frequently used definition of positive CTCs in HNSCC was by positivity for epithelial cell adhesion molecule (EpCAM) that is absent in normal blood mononuclear cells and negative CD45 staining that is specific to blood mononuclear cells (24, 32). The CellSearch system (Menarini Silicon Biosystems, Bologna, Italy) is, to date, the single Food and Drug Administration (FDA)-approved CTC detection and quantification platform. It performs immunomagnetic enrichment using ferrofluids with EpCAM antibodies coupled to an analyzer that captures images of isolated cells after staining with specific fluorescent antibodies. After immunomagnetic enrichment, recovered cells are permeabilized and stained with a nuclear stain (DAPI), and a fluorescent antibody conjugate against CD45 (leukocyte marker) and cytokeratins 8, 18, and 19 (epithelial markers). To be considered a CTC, a cell must be EpCAM positive, stain positive for nuclear DAPI, have a positive cytoplasmic appearance for cytokeratins and a negative leukocytic CD45 staining, having a diameter larger than 5 μm. The detection of more than 3–5 positive cells/7.5 ml of blood defines a positive sample and the detection limit is of 1 CTC/7.5 ml Ethylenediaminetetraacetic acid (EDTA)-blood (22, 31–34). The use of leucocytic marker CD45 for negative selection combined with immunofluorescence staining methods that use antibodies against N-cadherin, CD133, and multi-cytokeratin was also employed for the detection of CTCs in HNSCC (30).

We have shown in Table 1 the most significant studies published on CTCs in HNSCC and ESCC, using the CellSearch platform. In both the malignancies, the level of CTCs detected correlated with poor prognosis, shorter disease-free survival, or reduced response to treatment, the data being more robust for ESCC (35, 37, 39, 41).

In several studies, expression of the programmed death ligand 1 (PD-L1) immunotherapy target in CTCs was investigated, in order to identify possible responders to pembrolizumab therapy and prognostic estimation (26, 28). A study from Strati et al. has quantified PD-L1 expression on CTCs in peripheral blood samples of patients with HNSCC, using direct imaging through the CellSearch system, showing that the positivity to PD-L1 is associated with poor prognosis (28).

The microfluidic platform system (CTC-Chip) and the isolation by size of epithelial tumor cells filtration methods (Isolation by Size of Tumor cells - ISET) use the size of the CTC specific to each tumor type. The use of dimension detecting techniques can help identify both the circulating tumor microemboli and clusters, which may express the CD45 marker in some of the cells, therefore escaping methods that use CD45 antibodies negative selection (21, 28).

The utility of detecting CTCs was, in most of the studies, for prognostic purpose or personalized therapy, with no current proven benefit for early diagnosis of HNSCC. The most important roles of detecting CTCs are for identifying future targets of treatment, to evaluate treatment response and disease recurrence (21, 32, 34). Further translational applications consist in establishing in vitro disease models based on circulating cancer stem cells that could be used for drug development and personalized therapy. Proposed head and neck cancer stem cell transcription factors and biomarkers are CD44, CD133, ALDH, cMET, Oct-4, Nanog Sox2 (42, 43). The identification of CTC subpopulations in patients with recurrent HNSCC may have future applications in developing novel antitumoral targeted therapies.

CIRCULATING TUMOR CELLS IN ESCC

The current approach to therapy in ESCC is dependent on accurate estimation of the tumor staging and is conducted in a multidisciplinary way, involving endoscopist, radiologist, oncologist, and surgeon. An accurate pretherapeutic staging providing a clear picture of the disease spread is critical for optimal therapeutic choice, between endoscopic resection, surgery, radiochemotherapy, or systemic chemotherapy. As extraesophageal tumor recurrence is found in only approximately 50% of cases, one could imagine that micrometastases are frequently missed by current imaging modalities and responsible for frequent distant disease relapse (44). The detection of CTCs can improve our prognostic ability and enhance staging systems in ESCC. Our systematic literature search has identified several prospective cohort studies, published between 2007 and 2019 about the clinical utility of CTCs in ESCC. The studies included patients diagnosed in all stages of the disease, between I and IV as well as at different time points during the disease course, before or after treatment, consisting in surgery, radiotherapy, or chemotherapy (45, 46).

For detection and isolation of CTCs, there were used techniques selecting CTCs based on their antigenic surface profile and immune magnetic procedures or methods that use physical properties of the cells, such as cell size, specific density (gradient centrifugation enrichment), cellular electric charge properties (dielectrophoretic procedures), and the deformation ability (chip-based microfluidic CTC enrichment methods). Dedicated CTC isolation platforms such as CellSearch system and CanPatrol have also been used (40, 46–48). Usually, for detection of CTCs similar markers were used as in HNSCC, consisting in CD45 negativity, and positivity for DAPI, CEP8, and cytokeratins (CK18, CK19, and CK8) and EpCAM (38, 40, 45, 46). The use of CanPatrol system by Chen et al. further classified CTCs in epithelial, mesenchymal, and hybrid, using expression of markers such as EpCAM, CK, vimentin, and Twist by fluorescent probes. The authors found that mesenchymal CTC count is directly correlated with clinical stage and response to chemotherapy (47).

Several studies have investigated the expression of survivin in CTCs. Survivin is a protein in the family of the inhibitors of apoptosis and is frequently expressed in numerous carcinomas and only rarely within normal cells. It can be detected in many types of samples such as blood, urine, and sputum.
Survivin expressing CTCs are associated with invasiveness, high nodal status, and shorter overall survival (48, 49), however, no study concerning survivin expression in HNSCC was identified, so far. Similarly to HNSCC, the majority of the studies indicated that higher detection of CTCs count directly correlates with metastasis, recurrence, shorter disease-free survival, worse response to chemoradiotherapy (CRT), regardless of the expressing marker used for CTC detection (18, 38, 40, 46, 48–50).

The presence of CTCs in the blood is found in both the HNSCC and ESCC and, according to current knowledge, CTCs detection cannot discriminate between the two conditions.

**CELL-FREE DNA AND CTDNA IN HNSCC**

Cell-free DNA from the tumoral origin is called ctDNA and is represented by 140–170 bp DNA fragments that originate from necrotic or apoptotic tumoral cells. It can be used to detect tumor-specific genomic alterations such as somatic mutations and methylation profiles. It has been shown that the detection of specific genomic alterations of driver oncogenes, such as *TP53, EGFR,* and *KRAS* in ctDNA, has clinical utility for cancer screening, early diagnosis, and targeted treatment approach, identifying in patients with lung cancer, colorectal cancer, or pancreatic cancer subgroups that would benefit of specific chemotherapy regimens. According to the Catalogue of Somatic Mutations in Cancer (COSMIC) database, the most frequently mutated genes in HNSCC are *TP53* (44%), *LRP1B* (21%), *NOTCH1* (20%), *FAT1* (19%), and *KMT2D* (16%). More than 550 somatic variants in *TP53* have been described so far in HNSCC, the most frequently reported being *R175H, R248Q, R248W,* and *R273H* (51). One of the most important prognostic roles of identifying genomic alterations in cfDNA resides in the prediction of minimal residual disease, which is known as microscopic tumoral cells that are still present after a potentially curative treatment and that are associated with disease recurrence (52, 53).

Several PCR and NGS sequencing methods could be used to detect somatic mutations in cfDNA, such as digital droplet PCR (DDPCR), Competitive allele-specific TaqMan PCR (CAST-PCR), and NGS techniques with novel modifications and adaptations, such as safe-sequencing systems (Safe-SeqS) or Plasma sequencing (Plasma-Seq) (54–56). The various techniques have different limits of detection and could be used to investigate specific genomic alteration or a panel of target sequences. As shown in Table 2, the NGS and specified PCR techniques have been recently used to screen for and validate hotspot mutations in a targeted panel of genes, in HNSCC, by several study groups, including Braig et al. (61) and Wang et al. (63). Wang et al. have investigated genomic alterations in *TP53, CDKN2A, HRAS, NRAS, PIK3CA,* and HPV16 DNA in plasma or saliva from 93 patients with HNSCC, documenting a potential role for diagnosis of invasive HNSCC for this gene panel (63). Braig et al. identified by NGS that mutations in the RAS family genes are found in a subgroup of patients with HNSCC and correlate with disease progression, also after cetuximab treatment (61).

Mazurek et al. and Perdomo et al. have shown that somatic alterations of either *KRAS* and *EGFR* or *TP53, NOTCH1, CDKN2A, CAP8,* and *PTEN* could be used for the diagnostic purpose by liquid biopsy in HNSCC (59, 62). Perdomo et al. have proposed that *TP53* genomic alterations could be a suitable biomarker for early detection of HNSCC in patients with HPV negative (59).
TABLE 2 | Significant studies on cell-free DNA in HNSCC—clinical applications.

| Authors          | Year | Type of alteration | Type of cancer | Genes                                      | Stage of disease | Assay type                  | Timing of sampling | Utility             |
|------------------|------|--------------------|----------------|--------------------------------------------|------------------|----------------------------|--------------------|---------------------|
| Schmidt et al.   | 2018 | Mutation           | HNSCC          | PIK3CA                                     | III-IV           | Allele-specific Plex-PCR    | Before treatment   | Diagnosis and monitoring |
| Vos et al.       | 2017 | Methylation        | HNSCC          | SEPT9, SHOX2                               | -                | ACTB triplex qPCR           | Before treatment   | Diagnosis           |
| Perdomo et al.   | 2017 | Mutation           | HNSCC          | TP53; NOTCH1, CDKN2A, CASP8, PTEN          | I-IV             | NGS                        | -                  | Diagnosis           |
| Schrock et al.   | 2017 | Methylation        | HNSCC          | SEPT9, SHOX2                               | I-IV             | ACTB triplex qPCR           | Before and after treatment | Diagnosis and prognosis |
| Braig et al.     | 2016 | Mutation           | HNSCC          | EGFR exon 12; KRAS exon 2,3,4; NRAS exon 2,3,4; HRAS exon 2,3 | III-IV           | NGS                        | After chemotherapy | Prognosis and treatment response |
| Mazurek et al.   | 2015 | Mutation           | HNSCC          | KRAS G12C; p.E746-A750del EGFR             | I-IV             | TaqMan genotyping          | After CRT          | Diagnosis           |
| Wang et al.      | 2015 | Mutation           | HNSCC          | TP53, PIK3CA, CDKN2A, FBXW7, HRAS, NRAS    | I-IV             | Safe-SeqS PCR              | Before treatment   | Diagnosis           |
| Mydlarz et al.   | 2014 | Methylation        | HNSCC          | EDNRB, p16, DCC                           | I-IV             | Quantitative methylation specific PCR | Before treatment | Diagnosis           |
| Yang et al.      | 2014 | Methylation        | NPSCC          | RASSF1A, WIFI, DAPK1, RARB2                | I-IV             | MS HRM PCR                 | Before treatment   | Diagnosis and prognosis |
| Tian et al.      | 2013 | Methylation        | NPSCC          | RASSF1, CDKN2A, DLEC1, DAPK1, UCHL1        | I-IV             | qPCR                       | -                  | Diagnosis           |

Aberrant methylation profiles are genomic alteration marking the early events of carcinogenesis and quantitative measure of methylation in specific gene loci has emerged as a novel tool for early diagnosis, prognosis, and disease monitoring (60). Methylation can be determined using different technologies, such as quantitative PCR (qPCR) and methylation sensitive high-resolution melting PCR (MS-HRM PCR) (53, 60). In HNSCC, the most frequently investigated methylated targets were SEPT9, SHOX2, DAPK1, RASSF1A, and CDKN2A genes (53, 58, 60). Gene methylations of SEPT9 and SHOX2 were identified in patients with different types of HNSCC, regardless of tumor stage, and hypermethylation could be used as a valuable biomarker for diagnosis and prognosis. For diagnostic purpose, studies have shown a good specificity, over 90%, but a rather low sensitivity (about 50%) (58, 60). By investigating methylation profiles in cfDNA in patients with nasopharyngeal-squamous cell carcinoma, Tian et al. and Yang et al. have proposed that investigating a panel of markers leads to better results that a single methylation target (65, 66). Methylation of CDKN2A had a sensitivity of 22.5% and a specificity of 97%, methylation of DAPK1, a sensitivity of 51.4%, and a specificity of 90%, whereas the panel consisting of CDKN2A, DLEC1, DAPK1, and UCHL1 was found to have the highest specificity and sensitivity for HNSCC detection (66). In another study, the use of a methylation panel consisting of RASSF1, WIFI, DAPK1, and RARB2 had a sensitivity of 95.8% and a detection rate of early-stage disease of 90%, showing great promise for clinical application. The highest specificity was identified for methylations of RASSF1A gene (65).

CELL-FREE DNA AND CTDNA IN ESCC

Tumor-specific gene alterations detection in ESCC are currently explored as a novel type of biomarker useful for diagnosis and prognosis. In the COSMIC database, there are to date 2,236 samples of ESCC genomic profiles reported, indicating that the most frequently mutated genes are TP53 (58%), KMT2D (18%), NOTCH1 (16%), LRP1B (14%), and FAT1 (14%), similar to HNSCC top 5 genes. The most frequently identified TP53 somatic mutations are R175H, R282W, Y220C, R213*, R248Q, R248W, R273H, and R342* (51). Of these, R175H, R248Q, R248W, and R273H somatic alterations are also the most frequently encountered TP53 alterations in HNSCC (18, 67). A recent systematic review has presented the clinical utility of circulating cfDNA as a novel biomarker for esophageal cancer (67). In total, 59 abstracts and 20 full papers have been reviewed including ESCC and esophageal adenocarcinoma cases. Seven studies have included patients with ESCC.

The most significant studies reporting the utility of cfDNA in ESCC are depicted in Table 3. In a cohort of 137 patients with ESCC, Tian et al. have shown that the use of 5-hydroxymethylcytosine (5hmC)-based biomarkers has clinical utility for diagnosis of ESCC, achieving a sensitivity of 93.75% and a specificity of 85.71% (Area Under Curve = 0.972).
It has been shown that 5hmC, the oxidative product of 5-methylcytosine (5mC), reflects the epigenetic features in patients with cancer, as it is a relatively stable intermediate of active DNA demethylation, being currently regarded as a novel epigenetic hallmark of cancer (73).

In a pilot cohort of 13 patients with ESCC patients prior of resection and neoadjuvant therapy, Ueda et al. have shown that NGS using a panel of 53 cancer-related genes is an effective tool for detecting somatic alterations in plasma cfDNA. The assay was able to detect variant frequencies of 0.12–7.2% and the use of cfDNA analysis in clinical assessments of the tumor burden could help predict tumor recurrence in ESCC (74). The best diagnostic utility was identified for the presence of mutations in the following 4 genes TP53, FAT3, MLL3, and AJUBA. Using these somatic alterations, the authors achieved 78.9% specificity, 100% specificity, and 92.3% diagnostic accuracy. TP53 is also a frequently mutated target in HNSCC, but FAT3 and FAT4 rather than FAT3 are more frequently mutated in HNSCC, according to COSMIC.

In the study of Hagi et al., molecular barcode sequencing of the TP53 gene enabled comprehensive and highly sensitive detection of ctDNA in patients with ESCC, prior to resection and neoadjuvant therapy as well as after therapy (68).

Luo et al. have designed a sequencing panel with improved targeting, identifying significantly mutated genes by metanalysis of 532 ESCC genomes. The proposed gene panel consists of 90 genes, achieving 94 and 75% of sensitivity, respectively when detecting at least 1 or 2 mutant genes in patients with ESCC. Thus, the gene panel proposed by Luo et al. could be useful in ESCC diagnosis and disease monitoring following surgery (75). A comparison of pre- and postoperative plasma ctDNA using deep NGS sequencing has shown that some ctDNA mutations had a lower occurrence frequency or even disappeared postoperatively, providing useful cfDNA targets for disease recurrence.

Meng et al. have shown that cfDNA could potentially be used to monitor disease load in patients with ESCC, as somatic mutations could be detected in cfDNA of patients with stages IIA to IIBB presurgery, but at a lower frequency in cfDNA of the same patients postsurgery. Using an NGS panel of 483 genes they have shown that somatic alteration could be detected in cfDNA in genes involved in traditional cancer-related pathways: PI3K-Akt/mammalian target of rapamycin (mTOR) signaling, genes encoding proteoglycans or focal adhesion molecules, genes involved in FoxO signaling, chemokine signaling pathways, or Janus kinase - signal transducer and activator of transcription protein (JAK-STAT) signaling.

With the primary aim to determine whether detection of ctDNA after CRT is associated with risk of tumor progression Azad et al. have analyzed by NGS 802 hot spots in 607 genes for Single nucleotide polymorphisms (SNPs) previously associated with esophageal adenocarcinoma or squamous cell carcinoma, including hot spots in LRP1B and TP53 frequently identified in HNSCC. The study group comprised of 10 ESCC cases out of 45 esophageal cancers. The authors have shown that the median proportion of tumor-derived DNA out of the total cell-free DNA before treatment was only 0.07%, further documenting the fact that ultrasensitive assays are needed for the assessment of ctDNA from localized esophageal tumors. The detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival (76).

Due to the lack of studies including patients with both conditions, currently, it is difficult to discriminate between HNSCC and ESCC based only on ctDNA mutation analysis.

### NONCODING RNA EXPRESSION IN ESCC AND HNSCC LIQUID BIOPSY

MicroRNAs are currently among the most promising biomarkers studied in many types of cancers, including ESCC and HNSCC, with diagnostic and prognostic values. The miRNAs are regulatory molecules found in tumoral cells and in the blood stream, carried by exosomes and function as translation repressors. MiRNAs can have multiple roles, being functional regulators of cell proliferation, interacting with many signaling pathways.
pathways either as inhibitors or stimulators. Therefore, they can be upregulated or downregulated in various types of tumors (3, 77). MiRNAs can be quantified from formalin-fixed paraffin-embedded (FFPE) tumoral samples as well as from exosome or serum liquid biopsies, by qRT-PCR (78-80). Exosomes could be isolated using ultracentrifugation, filtration, chromatography, magnetic associated cell sorting, fluorescence, colorimetric ELISA assays, and other methods and are excellent miRNA carriers (3). Total exosomal RNA extraction followed by RT-PCR miRNA quantification is currently one of the best liquid biopsy approach for diagnosis and prognosis estimation in patients with cancer (81).

Our systematic literature search has identified 20 miRNAs and one lncRNA (HOTAIR) relevant for HNSCC and ESCC liquid biopsies. These miRNAs have multiple gene targets, in both ESCC and HNSCC.

miR-10 is a promising biomarker for ESCC and HNSCC, targeting T-cell lymphoma invasion and metastasis-inducing protein1 (TIAM1). In ESCC, *miR-10* downregulates TIAM1, reducing its expression. Increased TIAM1 expression is currently considered a negative prognostic factor in ESCC, as it is associated with increased histology grade, advanced clinical stages, and lymph node metastasis (82). Increased *miR-10* is a good prognostic indicator, being associated with the suppression of tumor growth and metastasis in ESCC via TIAM1 repression. In HNSCC, *miR-10* was identified in patients with oral squamous cell carcinoma, having the same target as in ESCC, TIAM1, but also HOXD10, RhoA/RhoC, and KLF4. *miR-10* has also diagnostic utility as it achieved 81.2% sensitivity and 80% specificity in the diagnosis of ESCC and 94.4% sensitivity and 80% specificity for HNSCC detection (83, 84). The main miRNA targets with diagnostic utility in HNSCC and ESCC and proposed signaling pathways are presented in Table 4.

A significant signaling pathway for ESCC and HNSCC pathogenesis is controlled by the transcription factor NF-kB and was found to be regulated by *miR-7, miR-9, miR-146a*, and *miR-34a* in ESCC and by *miR-125b* and *miR-146a* in HNSCC, respectively. Thus, *miR-146a* is involved in both malignancies via NF-kB pathway regulation, but it seems to have an opposite behavior, as it is downregulated in ESCC and up-regulated in HNSCC (82, 86, 105, 108, 111, 119).

Furthermore, among the evaluated miRNA targets, *miR-9, miR-21, miR-23, miR-141, miR-424*, and *miR-196a* were upregulated in both the cancers, as whereas *miR-7, miR-98, miR-122, miR-139, miR-200c*, and *miR-375* were downregulated in both the ESCC and HNSCC. These miRNA targets were associated with metastasis, invasion, tumoral cell growth, and poor prognosis in both the tumor types (85-87, 89, 90, 93–95, 98–101, 106, 107, 111–114, 122). Other miRNA targets could have utility for diagnosis or prognostic stratification as they were up-regulated in HNSCC and down-regulated in ESCC: *miR-10, miR-365a, miR-125b, miR-146a, miR-34a, miR-455*, and *miR574*. On the other hand, *miR-99b* was upregulated in ESCC and downregulated in HNSCC (78, 82-84, 86, 102–105, 108–110, 121, 123).

The potential roles of miRNAs in diagnosis, prognosis, and as possible therapeutic targets are given in Table 5. Of particular interest as a possible target for treatment is *miR-200c* since it was associated in both types of SCC with increased radiosensitivity. It controls G2/M checkpoint in DNA replication via p21 and BMI1 as well as ZEB1 and ZEB2 signaling pathways. *miR-200c* is downregulated in aggressive SCCs and its increased expression is associated with a better prognosis and a better response to radiotherapy (113, 114).

Homebox - HOX transcript antisense RNA (HOTAIR), a lncRNA was identified as a valuable biomarker for both HNSCC and ESCC, having regulatory effects in tumoral cells, by controlling proliferation, invasion, and differentiation. HOTAIR expression was directly correlated to the TNM stage. Its serum expression in patients at risk could be used also as a diagnostic tool, with a sensitivity of 56 and 94.2% and specificity of 90 and 73.5% for ESCC and for HNSCC, respectively (15, 117, 118).

In the future, circulating non-coding RNA expression could be one of the best methods to discriminate between ESCC and HNSCC and robust research studies including patients with both conditions and cohorts in which the two malignancies occur synchronous or metachronous are mandatory.

**CONCLUSION AND FUTURE RESEARCH DIRECTION**

Liquid biopsy as a field of research could be an important tool in the battle of discovering new biomarkers for early diagnosis, since both the HNSCC and ESCC are currently diagnosed in a late stage of disease, with advanced tumor locoregional invasion, associated with complications, metastases, and poor survival. Currently, in the approved clinical guidelines, there are no biomarkers proposed for early diagnosis in patients that are at risk. There are excellent reviews focused on liquid biopsy applications for individual malignancies. Recently, Mishra et al. have reviewed clinical applications of different liquid biopsy multifunctional biomarkers in head and neck cancers such as: somatic DNA mutations-based markers, methylation profiles, mitochondrial DNA-based biomarkers, exosomes and EVs, transcriptomic, nongenomic based biomarkers as well as CTCs, and viral-based biomarkers (124). Our extensive literature search, however, has identified no study, so far, addressing the topic of common or specific molecular biomarkers validated in patient cohorts with synchronous or metachronous HNSCC and ESCC, or at least studies including patients with both malignancies. This is still an unmet need, although one could imagine significant clinical applications in terms of early diagnosis and prognostic stratification. The present review is the first that has aimed to analyze current knowledge regarding the utility of liquid biopsy in both conditions and to provide potential targets for further research. The review was focused on common markers, as these could be identified based on published literature, in the lack of studies systematically addressing both malignancies with the same panel of molecular markers.

The current applications, strengths, and limitations of liquid biopsies have been recently reviewed by Martins et al. (125). The main strength of liquid biopsies resides in the non-invasive character of the procedures that could be applied repeatedly...
| Year | Type of RNA | Authors ESCC | Authors HNSCC/ type of HNSCC | Identified target gene ESCC | Identified target gene HNSCC | Signaling pathway ESCC/HNSCC | Diagnosis of ESCC | Diagnosis of HNSCC |
|------|-------------|--------------|-----------------------------|----------------------------|-----------------------------|-----------------------------|-----------------|-----------------|
| 2021 | miR-122     | Wang et al. (85) | Ruales et al. (86); LSCC | KIF22 | Bcl-W, CCNG1 | EMT pathway PI3K/Akt/mTOR / p70S6K | – | – |
| 2019 | miR-21      | Chen et al. (87); Wang et al. (88) | Avissar et al. (89); Wang et al. (90); OSCC | RASA1 | PDCD4, PTEN, MARCKS; | IGFL1 | – | 71% sensitivity and 96.9% specificity |
| 2019 | miR-98      | Huang et al. (91); OSCC | Du et al. (91); OSCC | EZH2 (High when miR98 is low) | | IGFL1 | – | – |
| 2019 | miR-10      | Liu et al. (92); Zhang et al. (93) | Lu et al. (83); OSCC | TIAM1 | HOXD10, TIAM1, RhoA/RhoC, KLF4 | P3K-Akt, MAPK | TIAM1-Rac1 | 81.2% sensitivity and 80% specificity |
| 2019 | miR-141     | Zhang et al. (94) | Ganci et al. (94); OSCC | YAP1, SOX17 | PTEN | – | – |
| 2019 | miR-139     | Jiao et al. (95) | Du et al. (91); OSCC | VEGRF1 | HOXA9 | – | – |
| 2019 | miR-375     | Luo et al. (96) | Wu et al. (97); OSCC | ARL4C; SLC7A11 | Wnt/b-catenin and EGF/RAS signaling | – | – |
| 2018 | miR-23      | Zhang et al. (98); miR-23b | Zhang et al. (98); (99); LSCC | EBF3 | APAF | TGFRα/SMAD activate miR-424 | P3K/Akt | – |
| 2018 | miR-424     | Wen et al. (100) | Li et al. (101); LSCC | PKCD, WEE1 | | PI3K/Akt | – |
| 2018 | miR-365a    | Sun et al. (102) | Geng et al. (103); LSCC | PSAT1 | p-AKT | – | – |
| 2018 | miR-125b    | Fan et al. (104) | Anitigada et al. (105); OSCC, LSCC | BMF; (BCL2 modifying factor) | A20 | – | – |
| 2018 | miR-196a    | Wang et al. (106) | Hu et al. (107) | IncRNA GASS | ANXA1 | – | – |
| 2018 | miR-34a     | Zuo et al. (108) | Kalfert et al. (109) | CD44 | NF-kB | – | – |
| 2018 | miR-455     | Liu et al. (110) | Cheng et al. (110); OSCC | Rab31; CGH/NK2; OEC-M1; SCC15; TW2.6 | TM3 | – | – |
| 2017 | miR-9       | Cui et al. (111) | Sun et al. (112); OSCC | E-cadherin | CXCR chemokine receptor 4 | NF-kB; MAPK, JAK 5/6, JAK, STAT, Hippo; Wnt/b-catenin signaling | 85.5% sensitivity and 98.5% specificity |
| 2017 | miR-200c    | Zheng et al. (113) | Lo et al. (114) | P21 | BM1 | – |
| 2017 | miR-99b     | Ma et al. (115); miR99b/let-7a/mir-125a cluster | Jakob et al. (116); OSCC | ARID3A, ZEB1 | – | Glycogen synthase kinase 3b | – |
| 2017 | HOTAIR (lncRNA) | Wang et al. (117) | Wang et al. (118); LSCC | HOTAIR | – | – |
| 2016 | miR-7       | Dong et al. (119) | Jiang et al. (120) | EGFR | IGFR1 | KLF4 and NF-kB; EGFR cell signaling | 78.1% sensitivity and 83.3% specificity |
| 2016 | miR-146a    | Liu et al. (121) | Ruales et al. (86); LSCC | IRS2; IL1 | Kinase-1 associated with IL1 receptor | EGFR and Wnt/b-catenin; NFkB pathway; NFkB pathway | – |
| 2016 | miR-574     | Okumura et al. (78) | Summerer et al. (121) | – | Wnt signaling pathway/EGFR | 93% sensitivity and 80% specificity | – | – |
| Year | Type of RNA | Authors ESCC | Authors HNSCC/type of HNSCC | Outcome ESCC | Outcome HNSCC | Utility in ESCC | Utility in HNSCC |
|------|-------------|--------------|----------------------------|--------------|--------------|----------------|---------------|
| 2021 | miR-122     | Wang et al.  | Ruales et al. (85); LSxCC | Down-regulation of KIF22 restrained malignant progression | Inhibition of tumorigenesis; role in diagnosis | Prognosis and treatment target | Diagnosis |
| 2019 | miR-21      | Chen et al.  | Avisar et al. (89); LSxCC | Role in proliferation, migration, invasion; Possible target of therapy | High expression - poor prognostic; Higher expression in OSCC | Diagnosis, Prognosis and treatment | Prognosis |
| 2019 | miR-98      | Huang et al. | Du et al. (91); OSCC | Tumor suppressor gene; Overexpression inhibit migration and invasion | Suppress cell migration and invasion | Prognosis | Prognosis |
| 2019 | miR-10      | Liu et al. (84); Zhang et al. (45) | Lu et al. (93); OSCC | Overexpression suppresses cell proliferation and enhances apoptosis; Potential target of therapy | Increase cell migration and invasion; | Diagnosis, Prognosis and treatment | Diagnosis, Prognosis |
| 2019 | miR-141     | Zhang et al. | Ganci et al. (94); OSCC | Promotes cell proliferation and inhibits apoptosis; Potential target of treatment | High expression correlates with shorter survival; Predict local recurrence; | Target of treatment | Prognosis |
| 2019 | miR-139     | Jiao et al.  | Wang et al. (122); OSCC | Role in inhibition of ESCC; Therapeutic target | Inhibits tumorigenesis and growth |Target of treatment and prognosis | Target of treatment |
| 2019 | miR-375     | Luo et al. (96) | Wu et al. (97); OSCC | Low expression correlates with poor prognosis | Downregulated in OSCC cells - tumor suppressor | Prognosis | Diagnosis and prognosis |
| 2018 | miR-23      | Zhang et al. | Zhang et al.; miR23a (93); LSxCC | Upregulation in ESCC and can induce proliferation, invasion and metastasis | Poor prognosis, greater extent of lymph node, worse clinical stage, short survival | Prognosis and metastasis | Prognosis |
| 2018 | miR-424     | Wen et al. (100) | Li et al. (101); LSxCC | Upregulation correlates with poor survival | High level-poor differentiation, advanced tumor stage | Prognosis and target of treatment | Target of treatment |
| 2018 | miR-365a    | Sun et al. (102) | Geng et al. (103); LSxCC | High levels inhibited cell invasion, colony formation and growth of tumoral cells | Promoted tumor growth and metastasis | Biomarker of development and progression | Target of treatment |
| 2018 | miR-196a    | Fan et al. (104) | Arriagada et al. (105); OSCC, LSxCC | Expression decreased; Overexpression inhibited tumor growth | High level-poor prognosis; metastasis, lower survival | Target of treatment and prognosis | Progression and metastasis |
| 2018 | miR-125b    | Wang et al. (106) | Hu et al. (107) | Suppress expression of GAS5 which functions as tumor suppressor gene. Is upregulated in ESCC tumor cells | Downregulation suppressed proliferation, invasion and migration of EC109 cells. May function as oncogene; | Diagnosis and target of treatment | Target of treatment |
| Year | Type of RNA | Authors ESCC | Authors HNSCC/type of HNSCC | Outcome ESCC | Outcome HNSCC | Utility in ESCC | Utility in HNSCC |
|------|-------------|--------------|-----------------------------|--------------|--------------|----------------|----------------|
| 2018 | miR-34a     | Zuo et al. (108) | Kalfert et al. (109) | Inhibited cell invasion, migration, tumor growth and metastasis, by regulating CD44 | Higher levels in p16 positive OSCC type. Acts as tumor suppressor | Prognosis | Prognosis and diagnosis |
| 2018 | miR-455     | Liu et al. (110) | Cheng et al. (110); OSCC | Overexpression inhibited proliferation, migration and invasion of Eca109 cells | Enhances proliferation and cell growth | Diagnosis and prognosis | Diagnosis |
| 2017 | miR-9       | Cui et al. (111) | Sun et al. (112); OSCC | High value–poor tumor differentiation, large size, deep invasion, lymph node, poor prognosis | low value- poor prognosis; tumor suppressive role | Diagnosis and prognosis | Prognosis |
| 2017 | miR-200c    | Zheng et al. (113) | Lo et al. (114) | Enhances radiosensitivity; Downregulation associated with radiotolerance; Effects in tumor migration and invasion inhibition | Overexpression reduces tumourigenicity and metastasis; enhances radiosensitivity; Role in radio-chemo-resistance | Target of treatment | Target of treatment |
| 2017 | miR-99b     | Ma et al. (115); miR99b/let-7e/mir-125a cluster | Jakob et al. (116); OSCC | Role in tumor metastasis. Enhanced cell mobility | Downregulation is associated with increased proliferation and colony formation | Prognosis | Prognosis |
| 2017 | HOTAIR; (lncRNA) | Wang et al. (117) | Wang et al. (118); LSACC | Potential biomarker of diagnosis;; Correlated with TNM stage;; Decreased after surgery | Higher levels in advanced stages; Correlates with miR-21 | Diagnosis | Diagnosis and prognosis |
| 2016 | miR-7       | Dong et al. (119) | Jiang et al. (120) | lower level correlates with longer tumor and status of lymph node | lower level correlates with increased risk, faster progression; independent of localization, T stage, treatment | Diagnosis and prognosis | Prognosis |
| 2016 | miR-146a    | Liu et al. (82) | Ruales et al. (86) | Suppressed EC109 and TE8 cell proliferation and invasion; Inhibited the expression of IRS2 | Overexpression—progression to metastasis | Target of treatment and diagnosis | Diagnosis and prognosis |
| 2016 | miR-574     | Okumura et al. (78) | Summerer et al. (121) | Tumor suppressor effect; | Reduced survival and poor prognosis after treatment; HPV independent marker | Prognosis | Prognostic |
to capture the molecular dynamics of the tumors. This is a major point with clinical impact considering the changing molecular characteristics of the tumors subjected to multimodal therapies. In comparison to traditional biopsies, liquid biopsies have the potential to better capture the intratumor molecular variability at different time points during follow-up. However, liquid biopsies have not yet fully entered daily practice as they require expensive equipment and trained personnel to conduct tests and interpret the results. There are also technology-specific limitations. CTCs are rarely found in the circulation and their isolation is difficult and costly. For cfDNA pre-analytical protocols lack standardization whereas the cfDNA template is found in specific body fluids at very low concentrations, leading to the low sensitivity of detection. Techniques to identify and isolate RNA species are still under development and one of the main challenges is the instability of the RNA molecule leading to difficulties in the identification of low abundance RNA species. The isolation and characterization of extracellular vesicles show great promise in the field of liquid biopsy. EVs could derive specifically from the tumor cells and are excellent carriers of tumor-related molecular information, but the lack of standardization of preanalytical protocols is still challenging.

The detection and quantification of CTCs have a minor role as a diagnostic tool, since they are usually discovered in the late stages of the disease and are related to extensive tumor spread and metastasis, having mainly a prognostic utility. The use of the FDA-approved Cellsearch platform has a good applicability for both ESCC and HNSCC. Circulating tumor DNA analysis shows promising perspectives for early diagnosis as studies have already indicated both common and specific somatic alterations but identified somatic variants should be further validated in independent series comprising both malignancies.

The investigation of methylation profiles seems to have the best utility for early diagnosis of both pathological conditions. Two years ago, using a ctDNA plasma methylation platform, the feasibility of cancer detection up to four years before the clinical cancer diagnostic in five common malignancies including esophageal cancer has been demonstrated (126). Almost at the same time, the results of an article that is a potential game changer have been published in the Annals of Oncology (127). The study included 6689 participants (2482 with more than 50 types of cancer and 4207 without cancer). The study used methylation patterns in cfDNA. The specificity of cancer detection was close to 100% and the sensitivity was 67.3% in 12 types of cancer including ESCC and HNSCC. The study did not specify whether any patients with both ESCC and HNSCC were included. Aside from methylation, TP53 somatic alterations could be proposed for screening purposes along with other somatic variants in frequently mutated genes such as KMT2D, NOTCH1, LRP1B, and FAT1. Specific polymorphisms could be integrated in screening panels with applicability for early diagnosis, detection of residual disease following surgery, or treatment response after radiochemotherapy.

Given the relationship of some head and neck cancers with viral infections, (Epstein-Barr virus (EBV) for nasopharynx cancers and human papilloma virus (HPV) for SCC of the oropharynx), it is likely that in the near future biomarkers related to these infections will be used routinely in the diagnostic and management of viral related cancers. Five years ago, a landmark article published in New England Journal of Medicine demonstrated the feasibility and usefulness of screening plasma EBV ctDNA in a population at high risk for nasopharynx cancer (128). Although less than 1/1000 HPV carriers develop cancer, at least in theory, a similar technique may be used also for early detection of HPV ctDNA in a population at risk, for example HPV carrier men (129).

Possibly the best field of research is translational regulation by noncoding RNAs, with applications for early diagnosis and prognostic stratification of both the patients with HNSCC and ESCC. There are currently multiple miRNA targets identified that behave similarly in both cancers as well as targets with opposite effects, some of them showing promising utility even as therapeutic targets.

However, none of the biomarkers described in this review can be used individually to robustly discriminate between ESCC and HNSCC. Further research is needed to integrate currently available molecular targets in biomarker panels, with clinical applicability for screening purposes and early diagnosis, detection of residual disease, and prognostic estimation. Given the different prognostic of these conditions, the discovery of specific molecular markers for each of these two malignancies remains an unmet need of paramount importance.

AUTHOR CONTRIBUTIONS

RI and MM have conducted the systematic literature search and generated the first draft of the manuscript. SI has updated CTC section of the manuscript and provided clinical background for the ESCC sections. CP has updated the cfDNA section. RH has conceived the general plan of the article, updated the miRNA section, and provided clinical background for the HNSCC sections. DP and CG have supervised the study and provided critical comments and review of the manuscript. All authors edited the manuscript and approved the submitted version.

REFERENCES

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. (2020).
2. Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. (2016) 91:386–96. doi: 10.1016/j.mayocp.2015.12.017
3. Yang W-Y, Feng L-F, Meng X, Chen R, Xu W-H, Hou J, et al. Liquid biopsy in head and neck squamous cell carcinoma: circulating tumor cells, circulating tumor DNA, and exosomes. Expert Rev Mol Diagn. (2020) 20:1213–27. doi: 10.1080/14737159.2020.1855977
4. McDermott JD, Bowles DW. Epidemiology of head and neck squamous cell carcinomas: impact on staging and prevention strategies. Curr Treat Options Oncol. (2019) 20:43. doi: 10.1007/s11864-019-0630-5
5. Kulasinghe A, Kenny I, Perry C, Thiery J-P, Jovanovic L, Vela I, et al. Impact of label-free technologies in head and neck cancer circulating tumour cells. *Oncotarget*. (2016) 7:12233–34. doi: 10.18632/oncotarget.12086

6. McLennan C, Chung CH, Hernandez-Perna JC. Evolving role of human papillomavirus as a clinically significant biomarker in head and neck squamous cell carcinoma. *Expert Rev Mol Diagn*. (2019) 19:63–70. doi: 10.1080/14737159.2019.1559056

7. Ibiyi Y, Nishiya M, Tsutani Y, Emi M, Hamai Y, Okada M, et al. Circulating microRNA/isoMiRs as novel biomarkers of esophageal squamous cell carcinoma. *PLoS ONE*. (2020) 15:e0231116. doi: 10.1371/journal.pone.0231116

8. Abnet CC, Arnold M, Wei W-Q. Epidemiology of esophageal squamous cell carcinoma. *Gastroenterology*. (2018) 154:360–73. doi: 10.1016/j.gastro.2017.08.023

9. Ohashi S, Miyamoto S, Ikuchi O, Goto T, Amanuma Y, Muto M. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. *Gastroenterology*. (2015) 149:1700–15. doi: 10.1016/j.gastro.2015.08.054

10. Swiecicki PL, Brennan JR, Mierzwa M, Spector ME, Brenner JC. Head and neck squamous cell carcinoma detection and surveillance: advances of liquid biomarkers. *Laryngoscope*. (2019) 129:1836–43. doi: 10.1002/lary.27725

11. Lim H, Kim DH, Jung HY, Gong EJ, Na HK, Ahn JY, et al. Clinical significance of early detection of esophageal cancer in patients with head and neck cancer. *Gut Liver*. (2015) 9:159–65. doi: 10.5090/gulj13041

12. Katada C, Muto M, Nakayama M, Tanabe S, Higuchi K, Sasaki T, et al. Risk of superficial squamous cell carcinoma developing in the head and neck region in patients with esophageal squamous cell carcinoma. *Laryngoscope*. (2012) 122:1291–6. doi: 10.1002/lary.23249

13. Leclere S, Antonietti M, Iwanicki-Caron I, Duclos A, Lemoine F, Pessot FL, et al. Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma. *Scientific Reports*. (2019) 9:258. doi: 10.1038/s41598-019-40160-5

14. Ghafouri-Fard S, Gholipour M, Taheri M, Shirvani Farsani Z. MicroRNA coding rnas in esophageal squamous cell carcinoma. *Cancers*. (2019) 11:3748. doi: 10.3390/cancers11113748

15. Chu L-Y, Peng Y-H, Weng X-F, Xie J-J, Xu Y-W. Blood-based biomarkers of esophageal squamous cell carcinoma treatment in real world clinical practice. *Int J Mol Sci*. (2020) 21:7621. doi: 10.3390/ijms2107621

16. Kulasinghe A, Kapelaris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery J-P, et al. The prognostic significance of circulating tumor cells in head and neck non-small-cell lung cancer. *Cancer Med*. (2018) 7:5910–9. doi: 10.1002/cam4.1832

17. Li J, Kang S, Zhang W, Tang X, Liu Y, Zhang Z, et al. Liquid biopsy: an emerging prognostic and predictive tool in Head and Neck squamous cell carcinoma (HNSCC). *PLoS ONE*. (2014) 9:e113706. doi: 10.1371/journal.pone.0113706

18. Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. *Ann Oncol*. (2017) 28:1923–33. doi: 10.1093/annonc/mdx206

19. Tinhofer I, Konshach R, Stromberger C, Rague J-D, Dreyer JH, Jøhrens K, et al. Detection of circulating tumor cells for prediction of recurrence after adjuvant chemoradiation in locally advanced squamous cell carcinoma of the head and neck. *Ann Oncol Off J Eur Soc Med Oncol*. (2014) 25:2042–7. doi: 10.1093/annonc/mdn271

20. Weller P, Nel I, Hassenkamp P, Gaulter T, Schlueer A, Lang S, et al. Detection of circulating tumor cell subpopulations in patients with head and neck squamous cell carcinoma (HNSCC). *PLoS ONE*. (2014) 9:e113706. doi: 10.1371/journal.pone.0113706

21. Zhou S, Wang L, Zhang W, Liu F, Zhang Y, Jiang B, et al. Circulating tumor cells correlate with prognosis in head and neck squamous cell carcinoma. *Technol Cancer Res Treat*. (2021) 20:1533033821990037. doi: 10.1177/1533033821990037

22. Wu X-L, Tu Q, Faure G, Gallet P, Kohler C, Bittencourt MDC. Diagnostic and prognostic value of circulating tumor cells in head and neck squamous cell carcinoma: a systematic review and meta-analysis. *Sci Rep*. (2016) 6:20210. doi: 10.1038/srep20210

23. Cohen SJ, Punt CJJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol Off J Am Soc Clin Oncol*. (2008) 26:3213–21. doi: 10.1200/JCO.2007.15.8923

24. Economopoulou P, Koutsodontis I, Kyrodimos E, Liandoudis ES, Psyrri A, Liquid biopsy: an emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). *Focus on Circulating Tumor Cells (CTCs) Oral Oncol*. (2017) 74:83–9. doi: 10.1016/j.oraloncology.2017.09.012

25. Gröbe A, Blessmann M, Hanken H, Friedrich RE, Schön G, Winkler J, et al. Prognostic and predictive role of circulating tumor cells in head and neck cancer. *Laryngoscope*. (2016) 126:232–9. doi: 10.1002/lary.24349

26. Li H, Song P, Zou B, Liu M, Cui K, Zhou P, et al. Circulating tumor cell analyses in patients with esophageal squamous cell carcinoma using epithelial marker-dependent and -independent approaches.
Iacob et al. Liquid Biopsy in HNSCC and ESCC

1. Galot R, Machiels J-PH. Current applications and challenges of circulating tumor cells in peripheral blood of patients with esophageal squamous cell carcinoma. *Ann Surg Oncol.* (2015) 22:3674–80. doi: 10.1007/s10434-015-4392-8

2. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: evolution of a cancer gene census. *Nucleic Acids Res.* (2013) 41:68–73. doi: 10.1093/nar/gks1211

3. Liu Z, Jiang M, Zhao J, Ju H. Circulating tumor cells in perioperative care of head and neck squamous cell carcinoma. *Stem Cells Int.* (2013) 2013:139489. doi: 10.1155/2013/139489

4. Makowiec F, Baier P, Kulemann B, Marjanovic G, Bronspet P, Zirlik K, et al. Long-term survival after esophagectomy for esophageal cancer: influence of epidemiologic shift and neoadjuvant therapy. *J Gastrointest Surg* Off J Soc Surg Aliment Tract. (2018) 17:1193–201. doi: 10.1007/s11608-018-3636-4

5. Quan P-L, Sauzade M, Brouzes E. dPCR: a technology review. *Sensors (Basel)*. (2018) 18:1271. doi: 10.3390/s18041271

6. Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. *Curr Protoc Mol Biol.* (2018) 122:e59. doi: 10.1002/cpmb.59

7. de Vos I, Gevensleben H, Dröge F, Franzen A, et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. *Clin Chem.* (2017) 63:1288–96. doi: 10.1373/clinchem.2016.270207

8. Yang X, Dai W, Kwong DL, Szeto CYY, Wong EH, Ng WT, et al. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. *Int J Cancer.* (2015) 136:1211–24. doi: 10.1002/ijc.31412

9. Tian X, Sun B, Chen C, Gao C, Zhang J, Lu X, et al. Circulating tumor DNA 5-hydroxymethylcytosine as a novel diagnostic biomarker for esophageal cancer. *Cell Res.* (2021) 31:22–37. doi: 10.1038/s41422-020-0307-8

10. Hibi K, Taguchi M, Nakayama H, Takase T, Kasai Y, Ito K, et al. Molecular Detection of strong, promoter methylation in the serum of patients with esophageal squamous cell carcinoma. *Clin Cancer Res.* (2001) 7:3135–8.
73. Vasanthakumar A, Godley LA. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. (2015) 208:167–77. doi: 10.1016/j.cancergen.2015.02.009
74. Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, et al. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget. (2016) 7:62290–91. doi: 10.18632/oncotarget.11409
75. Luo H, Li H, Hu Z, Wu H, Liu C, Li Y, et al. Noninvasive diagnosis and monitoring of mutations by deep sequencing of circulating tumor DNA in esophageal squamous cell carcinoma. Biochem Biophys Res Commun. (2016) 471:596–602. doi: 10.1016/j.bbrc.2016.02.011
76. Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, et al. The upregulation of miRNA-574-3p as a predictor of postoperative outcome of neck lymph node metastases in patients with head and neck squamous cell carcinoma. BMC Med. (2015) 13:108. doi: 10.1186/s12196-015-0350-3
77. Liu Y, Qiao Y, Escalada M, Hashimoto I, Hojo S, et al. Identification of miR-375 as a potential prognostic marker for esophageal squamous cell carcinoma. Cancer Prev Res (2017) 10:138–46. doi: 10.1158/1940-6207.CAPR-16-0358
78. Okumura T, Kojima H, Miwa T, Sekine S, Hirata H, Uchi R, et al. The expression of microRNA-23a in serum: a fingerprint for esophageal squamous cell cancer. Mol Cell Biochem. (2018) 443:104552. doi: 10.1007/s11010-017-1213-2
79. Vasanthakumar A, Godley LA. 5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. (2015) 208:167–77. doi: 10.1016/j.cancergen.2015.02.009
80. Wu C, Wang C, Guan X, Liu Y, Li D, Zhou H, et al. Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell cancer. PLoS ONE. (2014) 9:e92292. doi: 10.1371/journal.pone.0092292
81. Ueda M, Iguchi T, Masuda T, Nakahara Y, Hirata H, Uchi R, et al. MicroRNA profiling in the high altitude mestizo ecuadorian population. Diagn Pathol. (2018) 13:4152–66. doi: 10.1186/s13000-018-0176-2
82. Liu H, Ren G, Zhu L, Liu X, He X. The upregulation of miRNA-146a inhibited biological behaviors of ESCC through inhibition of IRS2. Tumour Biol J Int Soc Oncodevelopmental Biol Med. (2016) 37:4641–7. doi: 10.1007/s13277-015-3813-x
83. Luo H-S, Wu D-H. Identification of miR-375 as a potential prognostic biomarker for esophageal squamous cell cancer: a bioinformatics analysis based on TCGA and meta-analysis. Pathol Res Pract. (2019) 215:512–8. doi: 10.1016/j.prp.2019.01.009
84. Wang J, Yu P-Y, Yu J-P, Luo J-D, Sun Z-Q, Sun F, et al. KIF22 promotes the proliferation, migration and invasion in esophageal squamous cell carcinoma by targeting RASA1. Mol Cancer. (2019) 215:512–8. doi: 10.1016/j.molcancer.2018.10.043
85. Wang K, Chen D, Meng Y, Xu J, Zhang Q. Clinical evaluation of 4 types of microRNAs in oral squamous cell carcinoma cells by targeting CD44. Mol Cell Biochem. (2018) 443:139–49. doi: 10.1007/s11010-017-3218-3
86. Salazar-Ruales C, Arguello J-V, López-Cortés A, Cabrera-Andrade A, García-Cárdenas JM, Guevara-Ramírez P, et al. Salivary microRNAs for early diagnosis of laryngeal squamous cell carcinoma. Oral Dis. (2019) 25:1686–97. doi: 10.1111/odi.12805
87. Chen X, Cai S, Li B, Zhang X, Li W, Liang H, et al. MicroRNA-21 regulates the biological behavior of esophageal squamous cell carcinoma by targeting RASA1. Oncol Rep. (2019) 41:1627–37. doi: 10.3892/or.2019.6944
88. Wang W, Wang J, Liu Q, Feng J, Jia Q, Yang J, et al. MicroRNA-49A and microRNA-214 post-transcriptionally regulate enhancer of zeste homolog 2 and inhibit migration and invasion in human head and neck squamous cell carcinoma. Mol Cancer. (2012) 11:51. doi: 10.1186/1476-4598-11-51
109. Kalfert D, Pesta M, Kulda V, Topolcan O, Ryska A, Celakovsky P, et al. MicroRNA profile in site-specific head and neck squamous cell cancer. *Anticancer Res.* (2015) 35:2455–63.

110. Liu Y, Tang Y, Li P. Inhibitory effect of microRNA-455-5p on biological functions of esophageal squamous cell carcinoma Eca109 cells via Rab31. *Exp Ther Med.* (2018) 16:4959–66. doi: 10.3892/etm.2018.8820

111. Cui Y, Xue Y, Dong S, Zhang P. Plasma microRNA-9 as a diagnostic and prognostic biomarker in patients with esophageal squamous cell carcinoma. *J Int Med Res.* (2017) 45:1310–7. doi: 10.1177/0300060517709370

112. Sun L, Liu L, Fu H, Wang Q, Shi Y. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients. *Med Sci Monit.* (2016) 22:289–94. doi: 10.12659/MSM.895683

113. Zheng R, Liu Y, Zhang X, Zhao P, Deng Q. miRNA-200c enhances radiosensitivity of esophageal cancer by cell cycle arrest and targeting P21. *Biomed Pharmacother.* (2017) 90:517–23. doi: 10.1016/j.biopha.2017.04.006

114. Lo W-L, Yu C-C, Chiou G-Y, Chen Y-W, Huang P-I, Chien C-S, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. *J Pathol.* (2011) 223:482–95. doi: 10.1002/path.2826

115. Ma J, Zhan Y, Xu Z, Li Y, Luo A, Ding F, et al. ZEB1 induced miR-99b/let-7c/miR-125a cluster promotes invasion and metastasis in esophageal squamous cell carcinoma. *Cancer Lett.* (2017) 398:37–45. doi: 10.1016/j.canlet.2017.04.006

116. Jakob M, Mattes LM, Küffer S, Unger K, Hess J, Bertlich M, et al. MicroRNA expression patterns in oral squamous cell carcinoma: hsa-mir-99b-3p and hsa-mir-100-5p as novel prognostic markers for oral cancer. *Head Neck.* (2019) 41:3499–515. doi: 10.1002/hed.25866

117. Wang W, He X, Zheng Z, Ma X, Hu X, Wu D, et al. Serum HOTAIR as a novel diagnostic biomarker for esophageal squamous cell carcinoma. *Mol Cancer.* (2017) 16:75. doi: 10.1186/s12943-017-0643-6

118. Wang J, Zhou Y, Lu J, Sun Y, Xiao H, Liu M, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. *Med Oncol.* (2014) 31:148. doi: 10.1007/s12032-014-0148-8

119. Dong W, Li B, Wang J, Song Y, Zhang Z, Fu C, et al. Diagnostic and predictive significance of serum microRNA-7 in esophageal squamous cell carcinoma. *Oncol Rep.* (2016) 35:1449–56. doi: 10.3892/or.2015.4499

120. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, Kolokythas A, et al. MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. *Biochem J.* (2010) 432:199–205. doi: 10.1042/Bj0100859

121. Summerer I, Unger K, Braselmann H, Schuettrumpf L, Maihofer C, Baumeister P, et al. Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients. *Br J Cancer.* (2015) 113:76–82. doi: 10.1038/bjc.2015.111

122. Wang K, Jin J, Ma T, Zhai H. MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9. *J Cell Mol Med.* (2017) 21:3730–40. doi: 10.1111/jcmm.15382

123. Cheng C-M, Shah S-G, Huang C-C, Hsiao J-R, Chang J-Y. Up-regulation of miR-455-5p by the TGF-β-SMAD signalling axis promotes the proliferation of oral squamous cancer cells by targeting UBE2B. *J Pathol.* (2016) 240:38–49. doi: 10.1002/path.4752

124. Mishra V, Singh A, Chen X, Rosenberg AL, Pearson AT, Zhavoronkov A, et al. Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. *Br J Cancer.* (2022) 126:361–70. doi: 10.1038/s41416-021-01626-0

125. Martinis I, Ribeiro IP, Jorge J, Gonçalves AC, Sarmento-Ribeiro AB, Melo JB, et al. Liquid biopsies: Applications for cancer diagnosis and monitoring. *Genes (Basel).* (2021) 12:1–20. doi: 10.3390/genes12030349

126. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Ann Oncol Off J Eur Soc Med Oncol.* (2020) 31:745–59. doi: 10.1016/j.annonc.2020.02.011

127. Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. *Nat Commun.* (2020) 11:3475. doi: 10.1038/s41467-020-17316-z

128. Chan KCA, Woo JKS, King A, Zee BCY, Lam WKJ, Chan SL, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. *N Engl J Med.* (2017) 377:513–22. doi: 10.1056/NEJMoa1701717

129. Damerla RR, Lee NY, You D, Soni R, Shah R, Reyngold M, et al. Detection of early human papillomavirus-associated cancers by liquid biopsy. *JCO Precis Oncol.* (2019) 3:PO.18.00276. doi: 10.1200/PO.18.00276

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Iacob, Mandaec, Iacob, Pietrosanu, Paul, Hainarosie and Gheorghe. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.